An anti-VEGF ribozyme embedded within the adenoviral VAI sequence inhibits glioblastoma cell angiogenic potential in vitro

Journal of Vascular Research

Volumn 41, Issue 3, 2004, Pages 220-228

  Ciafrè, Silvia Anna ^a   Niola, Francesco ^a   Wannenes, Francesca ^a   Farace, Maria Giulia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Angiogenesis; Glioblastoma; Ribozyme; VAI; Vascular endothelial growth factor

Indexed keywords

RIBOZYME; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADENOVIRUS; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA SEQUENCE; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VIRUS GENOME;

ADENOVIRUSES, HUMAN; BASE SEQUENCE; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINATION, GENETIC; RNA, CATALYTIC; RNA, VIRAL; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2942701945     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077777     Document Type: Article

References (41)

1. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-858.
2. Holland EC: Glioblastoma multiforme: The terminator. Proc Natl Acad Sci USA 2000;97:6242-6244.
3. 3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer 2000;82:1967-1973.
4. Plate KH, Risau W: Angiogenesis in malignant gliomas. Glia 1995;15:339-347.
5. Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, Nose T: Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996;56:2185-2190.
6. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips S, Ferrara N: Inhibition of VEGF-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-844.
7. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis and growth of microtumors by anti-VEGF neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032-4039.
8. Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996;56:393-401.
9. Cheng S-Y, Su Huang H-J, Nagane M, Ji X-D, Wang D, Shih CC-Y, Arap W, Huang C-M, Cavenee WK: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996;93:8502-8507.
10. Benjamin LE, Keshet E: Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997;94:8761-8766.
11. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-165.
12. Gaughan DJ, Whitehead AS: Function and biological applications of catalytic nucleic acids. Biochim Biophys Acta 1999;1445:1-20.
13. Birikh KR, Heaton PA, Eckstein F: The structure, function and application of the hammerhead ribozyme. Eur J Biochem 1997;245:1-6.
14. Suzuki T, Anderegg B, Ohkawa T, Irie A, Engebraaten O, Halks-Miller M, Holm PS, Curiel DT, Kashani-Sabet M, Scanlon KJ: Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. Gene Ther 2000;7:241-248.
15. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB, von Zglinicki T: Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res 2001;61:3053-3061.
16. Prislei S, Buonomo SBC, Michienzi A, Bozzoni I: Use of adenoviral VAI small RNA as a carrier for cytoplasmic delivery of ribozymes. RNA 1997;3:677-687.
17. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
18. Zuker M, Mathews DH, Turner DH: Algorithms and thermodynamics for RNA secondary structure prediction: A practical guide; in Barciszewski J, Clark BFC (eds): RNA Biochemistry and Biotechnology. NATO ASI Series. Dordrecht, Kluwer Academic, 1999, pp 11-43.
19. Mathews DH, Sabina J, Zuker M, Turner DH: Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol 1999;288:911-940.
20. Thomas KA: Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996;271:603-606.
21. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin C-H: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-26995.
22. Folkman J, Klagsbrun M: Angiogenic factors. Science 1987;235:442-447.
23. Martiny-Baron G, Marmé D: VEGF-mediated tumour angiogenesis: A new target for cancer therapy. Curr Opin Biotechnol 1995;6:675-680.
24. Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A: Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 2002;277:14153-14158.
25. Tanaka M, Kijima H, Itoh J, Matsuda T, Tanaka T: Impaired expression of a human septin family gene Bradeion inhibits the growth and tumorigenesis of colorectal cancer in vitro and in vivo. Cancer Gene Ther 2002;9:483-488.
26. Parry TJ, Cushman C, Gallegos AM, Agrawal AB, Richardson M, Andrews LE, Maloney L, Mokler VR, Wincott FE, Pavco PA: Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res 1999;27:2569-2577.
27. Kowalski P, Stein U, Scheffer GL, Lage H: Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther 2002;9:579-586.
28. Ke LD, Fueyo J, Chen X, Steck PA, Shi Y-X, Im S-A, Yung A: A novel approach to glioma gene therapy: Down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes. Int J Oncol 1998;12:1391-1396.
29. Morino F, Tokunaga T, Tsuchida T, Handa A, Nagata J, Tomii Y, Kijima H, Yamazaki H, Watanabe N, Ueyama Y, Nakamura M: Hammerhead ribozyme specifically inhibits vascular endothelial growth factor gene expression in a human hepatocellular carcinoma cell line. Int J Oncol 2000;17:495-499.
30. Oshika Y, Nakamura M, Tokunaga T, Ohnishi Y, Abe Y, Tsushida T, Tomii Y, Kijima H, Yamazaki Y, Ozeki Y, Tamaoki N, Ueyama Y: Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC). Eur J Cancer 2000;36:2390-2396.
31. Tokunaga T, Abe Y, Tsuchida T, Hatanaka H, Oshika Y, Tomisawa M, Yoshimura M, Ohnishi Y, Kijima H, Yamazaki H, Ueyama Y, Nakamura M: Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line. Int J Oncol 2002;21:1027-1032.
32. Couture LA, Stinchcomb DT: Anti-gene therapy: The use of ribozymes to inhibit gene function. Trends Genet 1996;12:510-515.
33. Lieber A, Strauss M: Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol Cell Biol 1995;15:540-551.
34. Zakharchuk AN, Doronin KK, Karpov VA, Krougliak VA, Naroditsky BS: The fowl adenovirus type 1 (CELO) virus-associated RNAencoding gene: A new ribozyme-expression vector. Gene 1995;161:189-193.
35. Cagnon L, Cucchiarini M, Lefebvre JC, Doglio A: Protection of a T-cell line from human immunodeficiency virus replication by the stable expression of a short antisense RNA sequence carried by a shuttle RNA molecule. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:349-358.
36. Garrison BS, McCaffrey A, Kay MA: Inhibition of Poliovirus replication (abstract No. 789). Congress of American Society of Gene Therapy, 2002.
37. Mendoza-Maldonado R, Zentilin L, Fanin R, Giacca M: Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcrabl ribozymes with specific cellular compartmentalization. Cancer Gene Ther 2002;9:71-86.
38. Cagnon L, Rossi JJ: Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA I-ribozyme chimeric transcripts. Antisense Nucleic Acid Drug Dev 2000;10:251-261.
39. Ciafrè SA, Barillari G, Bongiorno Borbone L, Wannenes F, Izquierdo M, Farace MG: A tricistronic retroviral vector expressing natural antiangiogenic factors inhibits angiogenesis in vitro but is not able to block tumor progression in vivo. Gene Ther 2002;9:297-302.
40. Mishima K, Mazar AP, Gown A, Skelly M, Ji XD, Wang XD, Jones TR, Cavenee WK, Huang HJ: A peptide derived from the nonreceptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci USA 2000;97:8484-8489.
41. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F, Landre J, Pluderi M, Tomei G, Villani R, Carroll RS, Black PM, Bikfalvi A: Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-7506.